Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 9

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 9
---
 the 14th day of November, 2025

BETWEEN:

XENOTHERAPEUTICS, INC., a
company existing under the laws of Massachusetts,

(hereinafter called “Parent”)

- and -

XENO ACQUISITION CORP., a company existing under the laws of Delawareand a wholly-owned subsidiary of Parent,

(hereinafter called the
“Purchaser”)

- and -

REPARE THERAPEUTICS INC., a company existing under the laws of the Province of Québec,

(hereinafter called the “Company”)

- and -

solely for purposes of Section9.15, XOMA ROYALTY CORPORATION, a company existing under the laws of Nevada,

(hereinafter called
“XRC”)

WHEREASthe Purchaser wishes to acquire all of the issued and outstanding Common Shares (as hereinafter defined) in the
capital of the Company by way of a plan of arrangement under the provisions of the QBCA (as hereinafter defined), on the terms and subject to the conditions set forth in this Agreement;

AND WHEREASthe board of directors of the Company (the “Board of Directors” or “Board”), after consultation with
its financial and legal advisors and receiving recommendations from a transaction committee of the Board of Directors (the “Transaction Committee”), has unanimously determined that the Contemplated Transactions are in the best
interests of the Company and the Shareholders;

AND WHEREASin August 2024, the Company began a strategic
re-prioritization, and, in connection therewith, it has undertaken and continues to undertake the discontinuance and orderly wind-up of its business and operations,
including (i) concluding all research and development activities; (ii) disposing of or licensing-out all of its existing intellectual property and assets with a view of monetizing on those assets
with the ultimate objective of distributing all such proceeds to its shareholders; (iii) in connection with the foregoing, laying off nearly all of its workforce; and (iv) other activities consistent with the cessation of business
operations (collectively, the “Discontinuance”);

AND WHEREAS the Distribution is being made as part of the Discontinuance
pursuant to the terms hereof;

AND WHEREAS the Board of Directors has approved the entering into of this Agreement and the consummation of the
transactions contemplated herein and unanimously determined to recommend approval of the Arrangement by the Shareholders on the terms and subject